M-Screen Demo
UM Life Sciences Institute and Fisher Biosciences Announce UM Grant Winners
February 2, 2006
ANN ARBOR, Mich---The Center for Chemical Genomics Pilot Project Initiative, a collaboration between the University of Michigan Life Sciences Institute and Fisher Scientific International Inc. has awarded its first grants to UM researchers.
The funds will provide research support for up to two years, allowing University of Michigan scientists to conduct innovative research directed toward technology development relating to high throughput screening (HTS), small molecules synthesis, target detection and assay miniaturization.
Researchers receiving awards are Associate Professor of Electrical Engineering Jay Guo for "Label-free Optical Micro-Resonator Biosensor for High-throughput Screening Applications"; Life Sciences Institute Research Assistant Professor and Molecular, Cellular and Developmental Biology Assistant Professor Anuj Kumar for "High-Throughput FRET Screening in Yeast with Plasmid-Based FP Fusions"; Assistant Professor of Biomedical Engineering and Chemical Engineering Michael Mayer for "Efficient and Parallel Formation of Membrane Protein Arrays by Hydrogel-based Microcontact Printing", and Professor of Chemistry John Montgomery for "New Methods for Macrocycle Glycosylation."
The Initiative, announced in October 2005, is a five-year collaboration between the Biosciences group of Fisher Scientific International Inc. with the University of Michigan to develop new tools for genomic and proteomic research. The collaboration promotes opportunities for Fisher to combine its expertise with research at the Center for Chemical Genomics within the University of Michigan 's Life Sciences Institute.
The 2007 Pilot Project call for proposals will be released in the fall of 2006. Proposals should be consistent with the program theme of facilitating the development or use of HTS approaches within the academic community to speed the discovery of molecular research tools (e.g., ligands, imaging probes, and new activities of existing drugs). Proposals funded during 2006 may enter the competitive process for a second year of funding.
